🟢 Kamada is trading 8.7% up in pre-market on stronger U.S. rabies-treatment demand

Kamada is trading 8.7% up now at $9.62 as investors respond to increased U.S. rabies-treatment demand and the company’s confirmation of sufficient KedRAB supply.

• StoneX reiterated its Buy rating and $15.00 price target on September 18, citing the CDC advisory and KedRAB’s market position.
• The broader risk-on market supports the move, with the S&P 500 up 0.63% and Nasdaq up 0.92%.